アフリベルセプトバイオシミラーのグローバル市場インサイト・予測（～2028年）

• 英文タイトル：Global Aflibercept Biosimilars Market Insights, Forecast to 2028

• レポートコード：QY2207E10351 • 出版社/出版日：QYResearch / 2022年7月 • レポート形態：英文、PDF、127ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥735,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,102,500 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,470,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

新型コロナウイルス感染症のパンデミックにより、世界のアフリベルセプトバイオシミラーの市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にアフリベルセプトバイオシミラーの世界市場のxxx％を占める「硝子体内注射」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「湿性黄斑変性症」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 中国のアフリベルセプトバイオシミラーの市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパのアフリベルセプトバイオシミラー市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのアフリベルセプトバイオシミラー市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 アフリベルセプトバイオシミラーのグローバル主要メーカーには、Regeneron、Sanofi、Novartis、Genentech、Roche、Pfizer、Sartorius、Eli Lilly、Bayer、Amgen、PlantForm、PharmaPraxis、Samsung Bioepis、Centus、Cadila Pharmaceuticals、Dr Reddy's、Aurobindo Pharma、Biocad、MAbxience、Hetero、Biocon、Kirin Biologics、Mylan、BeiGene、Innovent、Qilu Pharmaceutical、Hengrui Pharmaceuticals、Hisun Pharmaceutical、TOT BIOPHARMなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 アフリベルセプトバイオシミラー市場は、種類と用途によって区分されます。世界のアフリベルセプトバイオシミラー市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 硝子体内注射、静脈内注射 【用途別セグメント】 湿性黄斑変性症、転移性大腸がん 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - アフリベルセプトバイオシミラー製品概要 - 種類別市場（硝子体内注射、静脈内注射） - 用途別市場（湿性黄斑変性症、転移性大腸がん） - 調査の目的 ・エグゼクティブサマリー - 世界のアフリベルセプトバイオシミラー販売量予測2017-2028 - 世界のアフリベルセプトバイオシミラー売上予測2017-2028 - アフリベルセプトバイオシミラーの地域別販売量 - アフリベルセプトバイオシミラーの地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別アフリベルセプトバイオシミラー販売量 - 主要メーカー別アフリベルセプトバイオシミラー売上 - 主要メーカー別アフリベルセプトバイオシミラー価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（硝子体内注射、静脈内注射） - アフリベルセプトバイオシミラーの種類別販売量 - アフリベルセプトバイオシミラーの種類別売上 - アフリベルセプトバイオシミラーの種類別価格 ・用途別市場規模（湿性黄斑変性症、転移性大腸がん） - アフリベルセプトバイオシミラーの用途別販売量 - アフリベルセプトバイオシミラーの用途別売上 - アフリベルセプトバイオシミラーの用途別価格 ・北米市場 - 北米のアフリベルセプトバイオシミラー市場規模（種類別、用途別） - 主要国別のアフリベルセプトバイオシミラー市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのアフリベルセプトバイオシミラー市場規模（種類別、用途別） - 主要国別のアフリベルセプトバイオシミラー市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のアフリベルセプトバイオシミラー市場規模（種類別、用途別） - 主要国別のアフリベルセプトバイオシミラー市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のアフリベルセプトバイオシミラー市場規模（種類別、用途別） - 主要国別のアフリベルセプトバイオシミラー市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのアフリベルセプトバイオシミラー市場規模（種類別、用途別） - 主要国別のアフリベルセプトバイオシミラー市場規模（トルコ、サウジアラビア） ・企業情報 Regeneron、Sanofi、Novartis、Genentech、Roche、Pfizer、Sartorius、Eli Lilly、Bayer、Amgen、PlantForm、PharmaPraxis、Samsung Bioepis、Centus、Cadila Pharmaceuticals、Dr Reddy's、Aurobindo Pharma、Biocad、MAbxience、Hetero、Biocon、Kirin Biologics、Mylan、BeiGene、Innovent、Qilu Pharmaceutical、Hengrui Pharmaceuticals、Hisun Pharmaceutical、TOT BIOPHARM ・産業チェーン及び販売チャネル分析 - アフリベルセプトバイオシミラーの産業チェーン分析 - アフリベルセプトバイオシミラーの原材料 - アフリベルセプトバイオシミラーの生産プロセス - アフリベルセプトバイオシミラーの販売及びマーケティング - アフリベルセプトバイオシミラーの主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - アフリベルセプトバイオシミラーの産業動向 - アフリベルセプトバイオシミラーのマーケットドライバー - アフリベルセプトバイオシミラーの課題 - アフリベルセプトバイオシミラーの阻害要因 ・主な調査結果

Aflibercept is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It is an inhibitor of vascular endothelial growth factor (VEGF).
Market Analysis and Insights: Global Aflibercept Biosimilars Market
Due to the COVID-19 pandemic, the global Aflibercept Biosimilars market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Intravitreal Injection accounting for % of the Aflibercept Biosimilars global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Wet Macular Degeneration segment is altered to an % CAGR throughout this forecast period.
China Aflibercept Biosimilars market size is valued at US$ million in 2021, while the US and Europe Aflibercept Biosimilars are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Aflibercept Biosimilars landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Aflibercept Biosimilars include Regeneron, Sanofi, Novartis, Genentech, Roche, Pfizer, Sartorius, Eli Lilly and Bayer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Aflibercept Biosimilars Scope and Segment
Aflibercept Biosimilars market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Aflibercept Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Intravitreal Injection
Intravenous Injection
Segment by Application
Wet Macular Degeneration
Metastatic Colorectal Cancer
By Company
Regeneron
Sanofi
Novartis
Genentech
Roche
Pfizer
Sartorius
Eli Lilly
Bayer
Amgen
PlantForm
PharmaPraxis
Samsung Bioepis
Centus
Cadila Pharmaceuticals
Dr Reddy’s
Aurobindo Pharma
Biocad
MAbxience
Hetero
Biocon
Kirin Biologics
Mylan
BeiGene
Innovent
Qilu Pharmaceutical
Hengrui Pharmaceuticals
Hisun Pharmaceutical
TOT BIOPHARM
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Aflibercept Biosimilars Product Introduction
1.2 Market by Type
1.2.1 Global Aflibercept Biosimilars Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Intravitreal Injection
1.2.3 Intravenous Injection
1.3 Market by Application
1.3.1 Global Aflibercept Biosimilars Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Wet Macular Degeneration
1.3.3 Metastatic Colorectal Cancer
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Aflibercept Biosimilars Sales Estimates and Forecasts 2017-2028
2.2 Global Aflibercept Biosimilars Revenue Estimates and Forecasts 2017-2028
2.3 Global Aflibercept Biosimilars Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Aflibercept Biosimilars Sales by Region
2.4.1 Global Aflibercept Biosimilars Sales by Region (2017-2022)
2.4.2 Global Sales Aflibercept Biosimilars by Region (2023-2028)
2.5 Global Aflibercept Biosimilars Revenue by Region
2.5.1 Global Aflibercept Biosimilars Revenue by Region (2017-2022)
2.5.2 Global Aflibercept Biosimilars Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Aflibercept Biosimilars Sales by Manufacturers
3.1.1 Global Top Aflibercept Biosimilars Manufacturers by Sales (2017-2022)
3.1.2 Global Aflibercept Biosimilars Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Aflibercept Biosimilars in 2021
3.2 Global Aflibercept Biosimilars Revenue by Manufacturers
3.2.1 Global Aflibercept Biosimilars Revenue by Manufacturers (2017-2022)
3.2.2 Global Aflibercept Biosimilars Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Aflibercept Biosimilars Revenue in 2021
3.3 Global Aflibercept Biosimilars Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Aflibercept Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Aflibercept Biosimilars Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Aflibercept Biosimilars Sales by Type
4.1.1 Global Aflibercept Biosimilars Historical Sales by Type (2017-2022)
4.1.2 Global Aflibercept Biosimilars Forecasted Sales by Type (2023-2028)
4.1.3 Global Aflibercept Biosimilars Sales Market Share by Type (2017-2028)
4.2 Global Aflibercept Biosimilars Revenue by Type
4.2.1 Global Aflibercept Biosimilars Historical Revenue by Type (2017-2022)
4.2.2 Global Aflibercept Biosimilars Forecasted Revenue by Type (2023-2028)
4.2.3 Global Aflibercept Biosimilars Revenue Market Share by Type (2017-2028)
4.3 Global Aflibercept Biosimilars Price by Type
4.3.1 Global Aflibercept Biosimilars Price by Type (2017-2022)
4.3.2 Global Aflibercept Biosimilars Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Aflibercept Biosimilars Sales by Application
5.1.1 Global Aflibercept Biosimilars Historical Sales by Application (2017-2022)
5.1.2 Global Aflibercept Biosimilars Forecasted Sales by Application (2023-2028)
5.1.3 Global Aflibercept Biosimilars Sales Market Share by Application (2017-2028)
5.2 Global Aflibercept Biosimilars Revenue by Application
5.2.1 Global Aflibercept Biosimilars Historical Revenue by Application (2017-2022)
5.2.2 Global Aflibercept Biosimilars Forecasted Revenue by Application (2023-2028)
5.2.3 Global Aflibercept Biosimilars Revenue Market Share by Application (2017-2028)
5.3 Global Aflibercept Biosimilars Price by Application
5.3.1 Global Aflibercept Biosimilars Price by Application (2017-2022)
5.3.2 Global Aflibercept Biosimilars Price Forecast by Application (2023-2028)
6 North America
6.1 North America Aflibercept Biosimilars Market Size by Type
6.1.1 North America Aflibercept Biosimilars Sales by Type (2017-2028)
6.1.2 North America Aflibercept Biosimilars Revenue by Type (2017-2028)
6.2 North America Aflibercept Biosimilars Market Size by Application
6.2.1 North America Aflibercept Biosimilars Sales by Application (2017-2028)
6.2.2 North America Aflibercept Biosimilars Revenue by Application (2017-2028)
6.3 North America Aflibercept Biosimilars Market Size by Country
6.3.1 North America Aflibercept Biosimilars Sales by Country (2017-2028)
6.3.2 North America Aflibercept Biosimilars Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Aflibercept Biosimilars Market Size by Type
7.1.1 Europe Aflibercept Biosimilars Sales by Type (2017-2028)
7.1.2 Europe Aflibercept Biosimilars Revenue by Type (2017-2028)
7.2 Europe Aflibercept Biosimilars Market Size by Application
7.2.1 Europe Aflibercept Biosimilars Sales by Application (2017-2028)
7.2.2 Europe Aflibercept Biosimilars Revenue by Application (2017-2028)
7.3 Europe Aflibercept Biosimilars Market Size by Country
7.3.1 Europe Aflibercept Biosimilars Sales by Country (2017-2028)
7.3.2 Europe Aflibercept Biosimilars Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Aflibercept Biosimilars Market Size by Type
8.1.1 Asia Pacific Aflibercept Biosimilars Sales by Type (2017-2028)
8.1.2 Asia Pacific Aflibercept Biosimilars Revenue by Type (2017-2028)
8.2 Asia Pacific Aflibercept Biosimilars Market Size by Application
8.2.1 Asia Pacific Aflibercept Biosimilars Sales by Application (2017-2028)
8.2.2 Asia Pacific Aflibercept Biosimilars Revenue by Application (2017-2028)
8.3 Asia Pacific Aflibercept Biosimilars Market Size by Region
8.3.1 Asia Pacific Aflibercept Biosimilars Sales by Region (2017-2028)
8.3.2 Asia Pacific Aflibercept Biosimilars Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Aflibercept Biosimilars Market Size by Type
9.1.1 Latin America Aflibercept Biosimilars Sales by Type (2017-2028)
9.1.2 Latin America Aflibercept Biosimilars Revenue by Type (2017-2028)
9.2 Latin America Aflibercept Biosimilars Market Size by Application
9.2.1 Latin America Aflibercept Biosimilars Sales by Application (2017-2028)
9.2.2 Latin America Aflibercept Biosimilars Revenue by Application (2017-2028)
9.3 Latin America Aflibercept Biosimilars Market Size by Country
9.3.1 Latin America Aflibercept Biosimilars Sales by Country (2017-2028)
9.3.2 Latin America Aflibercept Biosimilars Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Aflibercept Biosimilars Market Size by Type
10.1.1 Middle East and Africa Aflibercept Biosimilars Sales by Type (2017-2028)
10.1.2 Middle East and Africa Aflibercept Biosimilars Revenue by Type (2017-2028)
10.2 Middle East and Africa Aflibercept Biosimilars Market Size by Application
10.2.1 Middle East and Africa Aflibercept Biosimilars Sales by Application (2017-2028)
10.2.2 Middle East and Africa Aflibercept Biosimilars Revenue by Application (2017-2028)
10.3 Middle East and Africa Aflibercept Biosimilars Market Size by Country
10.3.1 Middle East and Africa Aflibercept Biosimilars Sales by Country (2017-2028)
10.3.2 Middle East and Africa Aflibercept Biosimilars Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Regeneron
11.1.1 Regeneron Corporation Information
11.1.2 Regeneron Overview
11.1.3 Regeneron Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Regeneron Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Regeneron Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Overview
11.2.3 Sanofi Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Sanofi Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Sanofi Recent Developments
11.3 Novartis
11.3.1 Novartis Corporation Information
11.3.2 Novartis Overview
11.3.3 Novartis Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Novartis Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Novartis Recent Developments
11.4 Genentech
11.4.1 Genentech Corporation Information
11.4.2 Genentech Overview
11.4.3 Genentech Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Genentech Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Genentech Recent Developments
11.5 Roche
11.5.1 Roche Corporation Information
11.5.2 Roche Overview
11.5.3 Roche Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Roche Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Roche Recent Developments
11.6 Pfizer
11.6.1 Pfizer Corporation Information
11.6.2 Pfizer Overview
11.6.3 Pfizer Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Pfizer Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Pfizer Recent Developments
11.7 Sartorius
11.7.1 Sartorius Corporation Information
11.7.2 Sartorius Overview
11.7.3 Sartorius Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Sartorius Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Sartorius Recent Developments
11.8 Eli Lilly
11.8.1 Eli Lilly Corporation Information
11.8.2 Eli Lilly Overview
11.8.3 Eli Lilly Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Eli Lilly Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Eli Lilly Recent Developments
11.9 Bayer
11.9.1 Bayer Corporation Information
11.9.2 Bayer Overview
11.9.3 Bayer Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Bayer Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Bayer Recent Developments
11.10 Amgen
11.10.1 Amgen Corporation Information
11.10.2 Amgen Overview
11.10.3 Amgen Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Amgen Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Amgen Recent Developments
11.11 PlantForm
11.11.1 PlantForm Corporation Information
11.11.2 PlantForm Overview
11.11.3 PlantForm Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 PlantForm Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 PlantForm Recent Developments
11.12 PharmaPraxis
11.12.1 PharmaPraxis Corporation Information
11.12.2 PharmaPraxis Overview
11.12.3 PharmaPraxis Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 PharmaPraxis Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 PharmaPraxis Recent Developments
11.13 Samsung Bioepis
11.13.1 Samsung Bioepis Corporation Information
11.13.2 Samsung Bioepis Overview
11.13.3 Samsung Bioepis Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Samsung Bioepis Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Samsung Bioepis Recent Developments
11.14 Centus
11.14.1 Centus Corporation Information
11.14.2 Centus Overview
11.14.3 Centus Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Centus Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Centus Recent Developments
11.15 Cadila Pharmaceuticals
11.15.1 Cadila Pharmaceuticals Corporation Information
11.15.2 Cadila Pharmaceuticals Overview
11.15.3 Cadila Pharmaceuticals Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Cadila Pharmaceuticals Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Cadila Pharmaceuticals Recent Developments
11.16 Dr Reddy’s
11.16.1 Dr Reddy’s Corporation Information
11.16.2 Dr Reddy’s Overview
11.16.3 Dr Reddy’s Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Dr Reddy’s Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Dr Reddy’s Recent Developments
11.17 Aurobindo Pharma
11.17.1 Aurobindo Pharma Corporation Information
11.17.2 Aurobindo Pharma Overview
11.17.3 Aurobindo Pharma Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Aurobindo Pharma Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Aurobindo Pharma Recent Developments
11.18 Biocad
11.18.1 Biocad Corporation Information
11.18.2 Biocad Overview
11.18.3 Biocad Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Biocad Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Biocad Recent Developments
11.19 MAbxience
11.19.1 MAbxience Corporation Information
11.19.2 MAbxience Overview
11.19.3 MAbxience Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 MAbxience Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 MAbxience Recent Developments
11.20 Hetero
11.20.1 Hetero Corporation Information
11.20.2 Hetero Overview
11.20.3 Hetero Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.20.4 Hetero Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.20.5 Hetero Recent Developments
11.21 Biocon
11.21.1 Biocon Corporation Information
11.21.2 Biocon Overview
11.21.3 Biocon Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.21.4 Biocon Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.21.5 Biocon Recent Developments
11.22 Kirin Biologics
11.22.1 Kirin Biologics Corporation Information
11.22.2 Kirin Biologics Overview
11.22.3 Kirin Biologics Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.22.4 Kirin Biologics Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.22.5 Kirin Biologics Recent Developments
11.23 Mylan
11.23.1 Mylan Corporation Information
11.23.2 Mylan Overview
11.23.3 Mylan Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.23.4 Mylan Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.23.5 Mylan Recent Developments
11.24 BeiGene
11.24.1 BeiGene Corporation Information
11.24.2 BeiGene Overview
11.24.3 BeiGene Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.24.4 BeiGene Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.24.5 BeiGene Recent Developments
11.25 Innovent
11.25.1 Innovent Corporation Information
11.25.2 Innovent Overview
11.25.3 Innovent Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.25.4 Innovent Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.25.5 Innovent Recent Developments
11.26 Qilu Pharmaceutical
11.26.1 Qilu Pharmaceutical Corporation Information
11.26.2 Qilu Pharmaceutical Overview
11.26.3 Qilu Pharmaceutical Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.26.4 Qilu Pharmaceutical Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.26.5 Qilu Pharmaceutical Recent Developments
11.27 Hengrui Pharmaceuticals
11.27.1 Hengrui Pharmaceuticals Corporation Information
11.27.2 Hengrui Pharmaceuticals Overview
11.27.3 Hengrui Pharmaceuticals Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.27.4 Hengrui Pharmaceuticals Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.27.5 Hengrui Pharmaceuticals Recent Developments
11.28 Hisun Pharmaceutical
11.28.1 Hisun Pharmaceutical Corporation Information
11.28.2 Hisun Pharmaceutical Overview
11.28.3 Hisun Pharmaceutical Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.28.4 Hisun Pharmaceutical Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.28.5 Hisun Pharmaceutical Recent Developments
11.29 TOT BIOPHARM
11.29.1 TOT BIOPHARM Corporation Information
11.29.2 TOT BIOPHARM Overview
11.29.3 TOT BIOPHARM Aflibercept Biosimilars Sales, Price, Revenue and Gross Margin (2017-2022)
11.29.4 TOT BIOPHARM Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
11.29.5 TOT BIOPHARM Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Aflibercept Biosimilars Industry Chain Analysis
12.2 Aflibercept Biosimilars Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Aflibercept Biosimilars Production Mode & Process
12.4 Aflibercept Biosimilars Sales and Marketing
12.4.1 Aflibercept Biosimilars Sales Channels
12.4.2 Aflibercept Biosimilars Distributors
12.5 Aflibercept Biosimilars Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Aflibercept Biosimilars Industry Trends
13.2 Aflibercept Biosimilars Market Drivers
13.3 Aflibercept Biosimilars Market Challenges
13.4 Aflibercept Biosimilars Market Restraints
14 Key Findings in The Global Aflibercept Biosimilars Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Aflibercept Biosimilars Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Intravitreal Injection
Table 3. Major Manufacturers of Intravenous Injection
Table 4. Global Aflibercept Biosimilars Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 5. Global Aflibercept Biosimilars Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Aflibercept Biosimilars Sales by Region (2017-2022) & (K Units)
Table 7. Global Aflibercept Biosimilars Sales Market Share by Region (2017-2022)
Table 8. Global Aflibercept Biosimilars Sales by Region (2023-2028) & (K Units)
Table 9. Global Aflibercept Biosimilars Sales Market Share by Region (2023-2028)
Table 10. Global Aflibercept Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 11. Global Aflibercept Biosimilars Revenue Market Share by Region (2017-2022)
Table 12. Global Aflibercept Biosimilars Revenue by Region (2023-2028) & (US$ Million)
Table 13. Global Aflibercept Biosimilars Revenue Market Share by Region (2023-2028)
Table 14. Global Aflibercept Biosimilars Sales by Manufacturers (2017-2022) & (K Units)
Table 15. Global Aflibercept Biosimilars Sales Share by Manufacturers (2017-2022)
Table 16. Global Aflibercept Biosimilars Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 17. Global Aflibercept Biosimilars Revenue Share by Manufacturers (2017-2022)
Table 18. Aflibercept Biosimilars Price by Manufacturers (2017-2022) &(K USD/Unit)
Table 19. Global Aflibercept Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Aflibercept Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Aflibercept Biosimilars as of 2021)
Table 21. Aflibercept Biosimilars Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Aflibercept Biosimilars Product Offered
Table 23. Date of Manufacturers Enter into Aflibercept Biosimilars Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Aflibercept Biosimilars Sales by Type (2017-2022) & (K Units)
Table 26. Global Aflibercept Biosimilars Sales by Type (2023-2028) & (K Units)
Table 27. Global Aflibercept Biosimilars Sales Share by Type (2017-2022)
Table 28. Global Aflibercept Biosimilars Sales Share by Type (2023-2028)
Table 29. Global Aflibercept Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 30. Global Aflibercept Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 31. Global Aflibercept Biosimilars Revenue Share by Type (2017-2022)
Table 32. Global Aflibercept Biosimilars Revenue Share by Type (2023-2028)
Table 33. Aflibercept Biosimilars Price by Type (2017-2022) & (K USD/Unit)
Table 34. Global Aflibercept Biosimilars Price Forecast by Type (2023-2028) & (K USD/Unit)
Table 35. Global Aflibercept Biosimilars Sales by Application (2017-2022) & (K Units)
Table 36. Global Aflibercept Biosimilars Sales by Application (2023-2028) & (K Units)
Table 37. Global Aflibercept Biosimilars Sales Share by Application (2017-2022)
Table 38. Global Aflibercept Biosimilars Sales Share by Application (2023-2028)
Table 39. Global Aflibercept Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 40. Global Aflibercept Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 41. Global Aflibercept Biosimilars Revenue Share by Application (2017-2022)
Table 42. Global Aflibercept Biosimilars Revenue Share by Application (2023-2028)
Table 43. Aflibercept Biosimilars Price by Application (2017-2022) & (K USD/Unit)
Table 44. Global Aflibercept Biosimilars Price Forecast by Application (2023-2028) & (K USD/Unit)
Table 45. North America Aflibercept Biosimilars Sales by Type (2017-2022) & (K Units)
Table 46. North America Aflibercept Biosimilars Sales by Type (2023-2028) & (K Units)
Table 47. North America Aflibercept Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 48. North America Aflibercept Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 49. North America Aflibercept Biosimilars Sales by Application (2017-2022) & (K Units)
Table 50. North America Aflibercept Biosimilars Sales by Application (2023-2028) & (K Units)
Table 51. North America Aflibercept Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 52. North America Aflibercept Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 53. North America Aflibercept Biosimilars Sales by Country (2017-2022) & (K Units)
Table 54. North America Aflibercept Biosimilars Sales by Country (2023-2028) & (K Units)
Table 55. North America Aflibercept Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 56. North America Aflibercept Biosimilars Revenue by Country (2023-2028) & (US$ Million)
Table 57. Europe Aflibercept Biosimilars Sales by Type (2017-2022) & (K Units)
Table 58. Europe Aflibercept Biosimilars Sales by Type (2023-2028) & (K Units)
Table 59. Europe Aflibercept Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 60. Europe Aflibercept Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 61. Europe Aflibercept Biosimilars Sales by Application (2017-2022) & (K Units)
Table 62. Europe Aflibercept Biosimilars Sales by Application (2023-2028) & (K Units)
Table 63. Europe Aflibercept Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 64. Europe Aflibercept Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 65. Europe Aflibercept Biosimilars Sales by Country (2017-2022) & (K Units)
Table 66. Europe Aflibercept Biosimilars Sales by Country (2023-2028) & (K Units)
Table 67. Europe Aflibercept Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 68. Europe Aflibercept Biosimilars Revenue by Country (2023-2028) & (US$ Million)
Table 69. Asia Pacific Aflibercept Biosimilars Sales by Type (2017-2022) & (K Units)
Table 70. Asia Pacific Aflibercept Biosimilars Sales by Type (2023-2028) & (K Units)
Table 71. Asia Pacific Aflibercept Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 72. Asia Pacific Aflibercept Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 73. Asia Pacific Aflibercept Biosimilars Sales by Application (2017-2022) & (K Units)
Table 74. Asia Pacific Aflibercept Biosimilars Sales by Application (2023-2028) & (K Units)
Table 75. Asia Pacific Aflibercept Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 76. Asia Pacific Aflibercept Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 77. Asia Pacific Aflibercept Biosimilars Sales by Region (2017-2022) & (K Units)
Table 78. Asia Pacific Aflibercept Biosimilars Sales by Region (2023-2028) & (K Units)
Table 79. Asia Pacific Aflibercept Biosimilars Revenue by Region (2017-2022) & (US$ Million)
Table 80. Asia Pacific Aflibercept Biosimilars Revenue by Region (2023-2028) & (US$ Million)
Table 81. Latin America Aflibercept Biosimilars Sales by Type (2017-2022) & (K Units)
Table 82. Latin America Aflibercept Biosimilars Sales by Type (2023-2028) & (K Units)
Table 83. Latin America Aflibercept Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 84. Latin America Aflibercept Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 85. Latin America Aflibercept Biosimilars Sales by Application (2017-2022) & (K Units)
Table 86. Latin America Aflibercept Biosimilars Sales by Application (2023-2028) & (K Units)
Table 87. Latin America Aflibercept Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 88. Latin America Aflibercept Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 89. Latin America Aflibercept Biosimilars Sales by Country (2017-2022) & (K Units)
Table 90. Latin America Aflibercept Biosimilars Sales by Country (2023-2028) & (K Units)
Table 91. Latin America Aflibercept Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 92. Latin America Aflibercept Biosimilars Revenue by Country (2023-2028) & (US$ Million)
Table 93. Middle East and Africa Aflibercept Biosimilars Sales by Type (2017-2022) & (K Units)
Table 94. Middle East and Africa Aflibercept Biosimilars Sales by Type (2023-2028) & (K Units)
Table 95. Middle East and Africa Aflibercept Biosimilars Revenue by Type (2017-2022) & (US$ Million)
Table 96. Middle East and Africa Aflibercept Biosimilars Revenue by Type (2023-2028) & (US$ Million)
Table 97. Middle East and Africa Aflibercept Biosimilars Sales by Application (2017-2022) & (K Units)
Table 98. Middle East and Africa Aflibercept Biosimilars Sales by Application (2023-2028) & (K Units)
Table 99. Middle East and Africa Aflibercept Biosimilars Revenue by Application (2017-2022) & (US$ Million)
Table 100. Middle East and Africa Aflibercept Biosimilars Revenue by Application (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Aflibercept Biosimilars Sales by Country (2017-2022) & (K Units)
Table 102. Middle East and Africa Aflibercept Biosimilars Sales by Country (2023-2028) & (K Units)
Table 103. Middle East and Africa Aflibercept Biosimilars Revenue by Country (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Aflibercept Biosimilars Revenue by Country (2023-2028) & (US$ Million)
Table 105. Regeneron Corporation Information
Table 106. Regeneron Description and Major Businesses
Table 107. Regeneron Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 108. Regeneron Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Regeneron Recent Developments
Table 110. Sanofi Corporation Information
Table 111. Sanofi Description and Major Businesses
Table 112. Sanofi Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 113. Sanofi Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Sanofi Recent Developments
Table 115. Novartis Corporation Information
Table 116. Novartis Description and Major Businesses
Table 117. Novartis Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 118. Novartis Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Novartis Recent Developments
Table 120. Genentech Corporation Information
Table 121. Genentech Description and Major Businesses
Table 122. Genentech Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 123. Genentech Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Genentech Recent Developments
Table 125. Roche Corporation Information
Table 126. Roche Description and Major Businesses
Table 127. Roche Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 128. Roche Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Roche Recent Developments
Table 130. Pfizer Corporation Information
Table 131. Pfizer Description and Major Businesses
Table 132. Pfizer Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 133. Pfizer Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Pfizer Recent Developments
Table 135. Sartorius Corporation Information
Table 136. Sartorius Description and Major Businesses
Table 137. Sartorius Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 138. Sartorius Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Sartorius Recent Developments
Table 140. Eli Lilly Corporation Information
Table 141. Eli Lilly Description and Major Businesses
Table 142. Eli Lilly Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 143. Eli Lilly Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. Eli Lilly Recent Developments
Table 145. Bayer Corporation Information
Table 146. Bayer Description and Major Businesses
Table 147. Bayer Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 148. Bayer Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 149. Bayer Recent Developments
Table 150. Amgen Corporation Information
Table 151. Amgen Description and Major Businesses
Table 152. Amgen Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 153. Amgen Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 154. Amgen Recent Developments
Table 155. PlantForm Corporation Information
Table 156. PlantForm Description and Major Businesses
Table 157. PlantForm Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 158. PlantForm Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 159. PlantForm Recent Developments
Table 160. PharmaPraxis Corporation Information
Table 161. PharmaPraxis Description and Major Businesses
Table 162. PharmaPraxis Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 163. PharmaPraxis Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 164. PharmaPraxis Recent Developments
Table 165. Samsung Bioepis Corporation Information
Table 166. Samsung Bioepis Description and Major Businesses
Table 167. Samsung Bioepis Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 168. Samsung Bioepis Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 169. Samsung Bioepis Recent Developments
Table 170. Centus Corporation Information
Table 171. Centus Description and Major Businesses
Table 172. Centus Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 173. Centus Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 174. Centus Recent Developments
Table 175. Cadila Pharmaceuticals Corporation Information
Table 176. Cadila Pharmaceuticals Description and Major Businesses
Table 177. Cadila Pharmaceuticals Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 178. Cadila Pharmaceuticals Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 179. Cadila Pharmaceuticals Recent Developments
Table 180. Dr Reddy's Corporation Information
Table 181. Dr Reddy's Description and Major Businesses
Table 182. Dr Reddy's Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 183. Dr Reddy's Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 184. Dr Reddy's Recent Developments
Table 185. Aurobindo Pharma Corporation Information
Table 186. Aurobindo Pharma Description and Major Businesses
Table 187. Aurobindo Pharma Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 188. Aurobindo Pharma Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 189. Aurobindo Pharma Recent Developments
Table 190. Biocad Corporation Information
Table 191. Biocad Description and Major Businesses
Table 192. Biocad Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 193. Biocad Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 194. Biocad Recent Developments
Table 195. MAbxience Corporation Information
Table 196. MAbxience Description and Major Businesses
Table 197. MAbxience Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 198. MAbxience Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 199. MAbxience Recent Developments
Table 200. Hetero Corporation Information
Table 201. Hetero Description and Major Businesses
Table 202. Hetero Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 203. Hetero Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 204. Hetero Recent Developments
Table 205. Biocon Corporation Information
Table 206. Biocon Description and Major Businesses
Table 207. Biocon Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 208. Biocon Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 209. Biocon Recent Developments
Table 210. Kirin Biologics Corporation Information
Table 211. Kirin Biologics Description and Major Businesses
Table 212. Kirin Biologics Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 213. Kirin Biologics Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 214. Kirin Biologics Recent Developments
Table 215. Mylan Corporation Information
Table 216. Mylan Description and Major Businesses
Table 217. Mylan Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 218. Mylan Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 219. Mylan Recent Developments
Table 220. BeiGene Corporation Information
Table 221. BeiGene Description and Major Businesses
Table 222. BeiGene Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 223. BeiGene Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 224. BeiGene Recent Developments
Table 225. Innovent Corporation Information
Table 226. Innovent Description and Major Businesses
Table 227. Innovent Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 228. Innovent Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 229. Innovent Recent Developments
Table 230. Qilu Pharmaceutical Corporation Information
Table 231. Qilu Pharmaceutical Description and Major Businesses
Table 232. Qilu Pharmaceutical Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 233. Qilu Pharmaceutical Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 234. Qilu Pharmaceutical Recent Developments
Table 235. Hengrui Pharmaceuticals Corporation Information
Table 236. Hengrui Pharmaceuticals Description and Major Businesses
Table 237. Hengrui Pharmaceuticals Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 238. Hengrui Pharmaceuticals Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 239. Hengrui Pharmaceuticals Recent Developments
Table 240. Hisun Pharmaceutical Corporation Information
Table 241. Hisun Pharmaceutical Description and Major Businesses
Table 242. Hisun Pharmaceutical Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 243. Hisun Pharmaceutical Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 244. Hisun Pharmaceutical Recent Developments
Table 245. TOT BIOPHARM Corporation Information
Table 246. TOT BIOPHARM Description and Major Businesses
Table 247. TOT BIOPHARM Aflibercept Biosimilars Sales (K Units), Revenue (US$ Million), Price (K USD/Unit) and Gross Margin (2017-2022)
Table 248. TOT BIOPHARM Aflibercept Biosimilars Product Model Numbers, Pictures, Descriptions and Specifications
Table 249. TOT BIOPHARM Recent Developments
Table 250. Key Raw Materials Lists
Table 251. Raw Materials Key Suppliers Lists
Table 252. Aflibercept Biosimilars Distributors List
Table 253. Aflibercept Biosimilars Customers List
Table 254. Aflibercept Biosimilars Market Trends
Table 255. Aflibercept Biosimilars Market Drivers
Table 256. Aflibercept Biosimilars Market Challenges
Table 257. Aflibercept Biosimilars Market Restraints
Table 258. Research Programs/Design for This Report
Table 259. Key Data Information from Secondary Sources
Table 260. Key Data Information from Primary Sources
List of Figures
Figure 1. Aflibercept Biosimilars Product Picture
Figure 3. Global Aflibercept Biosimilars Market Share by Type in 2021 & 2028
Figure 3. Intravitreal Injection Product Picture
Figure 4. Intravenous Injection Product Picture
Figure 5. Global Aflibercept Biosimilars Market Share by Application in 2021 & 2028
Figure 6. Wet Macular Degeneration
Figure 7. Metastatic Colorectal Cancer
Figure 8. Aflibercept Biosimilars Report Years Considered
Figure 9. Global Aflibercept Biosimilars Sales 2017-2028 (K Units)
Figure 10. Global Aflibercept Biosimilars Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Aflibercept Biosimilars Revenue 2017-2028 (US$ Million)
Figure 12. Global Aflibercept Biosimilars Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 13. Global Aflibercept Biosimilars Sales Market Share by Region (2017-2022)
Figure 14. Global Aflibercept Biosimilars Sales Market Share by Region (2023-2028)
Figure 15. North America Aflibercept Biosimilars Sales YoY (2017-2028) & (K Units)
Figure 16. North America Aflibercept Biosimilars Revenue YoY (2017-2028) & (US$ Million)
Figure 17. Europe Aflibercept Biosimilars Sales YoY (2017-2028) & (K Units)
Figure 18. Europe Aflibercept Biosimilars Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Asia-Pacific Aflibercept Biosimilars Sales YoY (2017-2028) & (K Units)
Figure 20. Asia-Pacific Aflibercept Biosimilars Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Latin America Aflibercept Biosimilars Sales YoY (2017-2028) & (K Units)
Figure 22. Latin America Aflibercept Biosimilars Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Middle East & Africa Aflibercept Biosimilars Sales YoY (2017-2028) & (K Units)
Figure 24. Middle East & Africa Aflibercept Biosimilars Revenue YoY (2017-2028) & (US$ Million)
Figure 25. The Aflibercept Biosimilars Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 26. The Top 5 and 10 Largest Manufacturers of Aflibercept Biosimilars in the World: Market Share by Aflibercept Biosimilars Revenue in 2021
Figure 27. Global Aflibercept Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 28. Global Aflibercept Biosimilars Sales Market Share by Type (2017-2028)
Figure 29. Global Aflibercept Biosimilars Revenue Market Share by Type (2017-2028)
Figure 30. Global Aflibercept Biosimilars Sales Market Share by Application (2017-2028)
Figure 31. Global Aflibercept Biosimilars Revenue Market Share by Application (2017-2028)
Figure 32. North America Aflibercept Biosimilars Sales Market Share by Type (2017-2028)
Figure 33. North America Aflibercept Biosimilars Revenue Market Share by Type (2017-2028)
Figure 34. North America Aflibercept Biosimilars Sales Market Share by Application (2017-2028)
Figure 35. North America Aflibercept Biosimilars Revenue Market Share by Application (2017-2028)
Figure 36. North America Aflibercept Biosimilars Sales Share by Country (2017-2028)
Figure 37. North America Aflibercept Biosimilars Revenue Share by Country (2017-2028)
Figure 38. United States Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 39. Canada Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 40. Europe Aflibercept Biosimilars Sales Market Share by Type (2017-2028)
Figure 41. Europe Aflibercept Biosimilars Revenue Market Share by Type (2017-2028)
Figure 42. Europe Aflibercept Biosimilars Sales Market Share by Application (2017-2028)
Figure 43. Europe Aflibercept Biosimilars Revenue Market Share by Application (2017-2028)
Figure 44. Europe Aflibercept Biosimilars Sales Share by Country (2017-2028)
Figure 45. Europe Aflibercept Biosimilars Revenue Share by Country (2017-2028)
Figure 46. Germany Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 47. France Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 48. U.K. Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 49. Italy Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 50. Russia Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 51. Asia Pacific Aflibercept Biosimilars Sales Market Share by Type (2017-2028)
Figure 52. Asia Pacific Aflibercept Biosimilars Revenue Market Share by Type (2017-2028)
Figure 53. Asia Pacific Aflibercept Biosimilars Sales Market Share by Application (2017-2028)
Figure 54. Asia Pacific Aflibercept Biosimilars Revenue Market Share by Application (2017-2028)
Figure 55. Asia Pacific Aflibercept Biosimilars Sales Share by Region (2017-2028)
Figure 56. Asia Pacific Aflibercept Biosimilars Revenue Share by Region (2017-2028)
Figure 57. China Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 58. Japan Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 59. South Korea Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 60. India Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 61. Australia Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 62. China Taiwan Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 63. Indonesia Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 64. Thailand Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 65. Malaysia Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 66. Latin America Aflibercept Biosimilars Sales Market Share by Type (2017-2028)
Figure 67. Latin America Aflibercept Biosimilars Revenue Market Share by Type (2017-2028)
Figure 68. Latin America Aflibercept Biosimilars Sales Market Share by Application (2017-2028)
Figure 69. Latin America Aflibercept Biosimilars Revenue Market Share by Application (2017-2028)
Figure 70. Latin America Aflibercept Biosimilars Sales Share by Country (2017-2028)
Figure 71. Latin America Aflibercept Biosimilars Revenue Share by Country (2017-2028)
Figure 72. Mexico Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 73. Brazil Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 74. Argentina Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 75. Middle East and Africa Aflibercept Biosimilars Sales Market Share by Type (2017-2028)
Figure 76. Middle East and Africa Aflibercept Biosimilars Revenue Market Share by Type (2017-2028)
Figure 77. Middle East and Africa Aflibercept Biosimilars Sales Market Share by Application (2017-2028)
Figure 78. Middle East and Africa Aflibercept Biosimilars Revenue Market Share by Application (2017-2028)
Figure 79. Middle East and Africa Aflibercept Biosimilars Sales Share by Country (2017-2028)
Figure 80. Middle East and Africa Aflibercept Biosimilars Revenue Share by Country (2017-2028)
Figure 81. Turkey Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 82. Saudi Arabia Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 83. UAE Aflibercept Biosimilars Revenue (2017-2028) & (US$ Million)
Figure 84. Aflibercept Biosimilars Value Chain
Figure 85. Aflibercept Biosimilars Production Process
Figure 86. Channels of Distribution
Figure 87. Distributors Profiles
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed

---